RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $43 from $46 and keeps a Sector Perform rating on the shares. The firm notes that competitive pressures could still see shares slide 5%-10% after its competitor Merck (MRK) reported data from their HIF-2alpha inhibitors study, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
- Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
- Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
- Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
- Exelixis price target raised to $54 from $52 at H.C. Wainwright